Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 92
Filter
1.
Z Rheumatol ; 2023 Aug 25.
Article in German | MEDLINE | ID: mdl-37624374

ABSTRACT

The term Castleman's disease encompasses a group of rare lymphoproliferative diseases that show histopathological similarities in lymph node biopsy. Diagnostic criteria and a specific ICD-10 code have been available for a few years. Case studies listed at the beginning illustrate that close cooperation between clinicians and pathologists is required to enable a reliable diagnosis. For an optimal histopathological assessment, the pathologist is also dependent on the removal of a complete lymph node. Before distinguishing a potentially fatal multicentric idiopathic Castleman's disease from the resectable unicentric form, which is important in terms of prognosis and treatment, early diagnosis presupposes that Castleman's disease is considered in the differential diagnosis. Various immune phenomena and overlaps with autoimmune diseases can increase the probability of misdiagnosis or undetected cases in the clinical routine of rheumatologists. The intention of the present overview is therefore to point out the similarities with autoimmune diseases that are relevant for differential diagnoses and to point out situations that justify a review of the previous diagnosis.

2.
Pathol Res Pract ; 227: 153651, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34673351

ABSTRACT

Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint inhibitors (ICI). The aim is to evaluate the association between the expression of 5 biomarkers involved in the immune response (CD73, CD39, VISTA, Arl4d and Cytohesin-3) in parallel with the more common ICI-predictive markers, PD-L1 expression and Tumor Mutation Burden (TMB) with response to ICI therapy in an advanced non-small cell lung cancer (NSCLC) cohort. METHODS: Patients with advanced NSCLC treated with ICI single agent were divided into responders and non-responders according to RECIST v1.1 and duration of response (DOR) criteria. Immunohistochemistry was performed on pretreatment tumor tissue samples for PD-L1, CD73, CD39, VISTA, Arl4d, and Cytohesin-3 expression. TMB was estimated with NEOplus v2 RUO (NEO New Oncology GmbH) hybrid capture next generation sequencing assay. Resistance mutations in STK11/KEAP1 and positive predictive mutations in ARID1A/POLE were also evaluated. RESULTS: Included were 56 patients who were treated with ICI single agent. The median progression-free and overall survival for the whole cohort was 3.0 (95% CI, 2.4-3.6) and 15 (95% CI, 9.7-20.2) months, respectively. The distribution of CD73 in tumor cells and CD39, VISTA, Arl4d and Cytohesin-3 expression in immune cells were not different between responders and non-responders. Also, PD-L1 and TMB were not predictive for response. The frequency of STK11, KEAP1 and ARID1A mutations was low and only observed in the non-responder group. CONCLUSION: Separate and combined expression of 5 biomarkers involved in the immune response (CD73, CD39, VISTA, Arl4d, and Cytohesin-3) was not associated with response in our cohort of advanced NSCLC patients receiving single agent ICI. To confirm our findings the analysis of independent larger cohorts is warranted.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/drug therapy , Immune Checkpoint Inhibitors/therapeutic use , Lung Neoplasms/drug therapy , Nivolumab/therapeutic use , 5'-Nucleotidase/analysis , ADP-Ribosylation Factors/analysis , Aged , Aged, 80 and over , Apyrase/analysis , B7 Antigens/analysis , Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/enzymology , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/mortality , Disease Progression , Female , GPI-Linked Proteins/analysis , Humans , Immunohistochemistry , Lung Neoplasms/enzymology , Lung Neoplasms/immunology , Lung Neoplasms/mortality , Male , Middle Aged , Mutation , Predictive Value of Tests , Progression-Free Survival , Receptors, Cytoplasmic and Nuclear/analysis , Time Factors
3.
Acta Histochem ; 123(4): 151711, 2021 May.
Article in English | MEDLINE | ID: mdl-33838578

ABSTRACT

To increase the efficiency of interpretation of mast cell's contribution to the state of a specific tissue microenvironment, it is necessary to detail the molecular composition of their secretome and analyze the pathways of degranulation. Developed method of combining immunomorphological and histochemical staining protocols contributes to the most objective detection of the integral level of tryptase expression in the intraorgan population of the skin mast cells. Novel technique for tryptase detection expands the possibilities of morphological analysis, provides researchers with additional data on the structure of the mast cell population and helps visualize the processing and cytological features and structural targets of tryptase during the development of adaptive and pathological reactions. Objective determination of the tryptase profile for organ-specific mast cell populations is in great demand in clinical practice for the interpretation of pathological processes, including inflammation and oncogenesis.


Subject(s)
Gene Expression Regulation, Enzymologic , Mast Cells , Skin , Staining and Labeling , Tryptases/biosynthesis , Animals , Male , Mast Cells/cytology , Mast Cells/enzymology , Organ Specificity , Rats , Rats, Wistar , Skin/cytology , Skin/enzymology
4.
Pneumologie ; 72(9): 617-623, 2018 Sep.
Article in German | MEDLINE | ID: mdl-30071539

ABSTRACT

Performing rebiopsies for primary lung cancer and/or their metastases is becoming more and more prominent in daily practice, as the therapeutical spectrum increases and some newer strategies are dependent on immunohistochemical and/or molecular factors. In general, nearly all recurrent lesions or metastases can be reached. However, frequently invasive procedures are necessary with the need to carefully weigh risks and benefits of rebiopsies for the patient in each case. In this review indications for recurrent and progressive disease as well as risks are discussed and alternatives to rebiopsies are shown. This work is the joint opinion from both the endoscopic and thoracic oncology sections of the German Society of Pneumology (DGP).


Subject(s)
Biopsy , Lung Neoplasms/pathology , Pulmonary Medicine , Germany , Humans , Societies, Medical
5.
Pathologe ; 37(6): 557-567, 2016 Nov.
Article in German | MEDLINE | ID: mdl-27510417

ABSTRACT

BACKGROUND: Antibodies against PD-1 and PD-L1 can cause strong and durable anti-tumor immune responses in non-small cell lung cancer (NSCLC). Immunohistochemistry for PD-L1 (PD-L1 IHC) was tested as a predictive biomarker. Several IHC assays and interpretation criteria were developed in parallel. AIM: The clinical significance of PD-L1 IHC in NSCLC and the optimum method for staining and interpretation of the results are the subject of ongoing studies. The diagnostic application of immunotherapy in NSCLC necessitates harmonization of PD-L1 IHC to obtain evidence for guidelines; therefore, a consensus opinion on a well-founded diagnostic mode of testing should be defined based on published studies and the results of the first German PD-L1 IHC harmonization study. METHODS: 1. Summary of the current data situation. 2. Evaluation of the first German PD-L1 IHC harmonization study (centralized, staining with PD-L1 IHC analogous to studies, 15 cases of NSCLC, 4 IHC study assays [28­8, 22C3, SP142 and SP263] and scoring by 9 pathologists). RESULTS: The use of PD-L1 IHC in NSCLC is suitable for identification of patients with an increased probability of a clinical benefit from immunotherapy. The various proportional cut-offs used to interpret the staining results can be summarized in a total score, which can be reproducibly assessed. The staining patterns of the four assays investigated were, however, not congruent in all situations. DISCUSSION: In principle, the use of PD-L1 IHC for assessment of the expression in tumor cells is a reliably determinable biomarker. Evaluation algorithms should be based on published clinical trials. For NSCLC approvals with obligatory PD-L1 IHC are to be expected but it remains to be seen to what extent PD-L1 IHC will be implemented in the clinical routine.


Subject(s)
B7-H1 Antigen/analysis , B7-H1 Antigen/immunology , Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Algorithms , Antibodies, Monoclonal/therapeutic use , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/therapy , Immunohistochemistry , Immunotherapy , Lung Neoplasms/immunology , Lung Neoplasms/therapy , Predictive Value of Tests , Prognosis
6.
Article in German | MEDLINE | ID: mdl-23978982

ABSTRACT

Physical activities are particularly health effective when they are structured and systematically organized, for example, with respect to a dose-response relationship or to psychosocial aspects. Which insights can be gained from scientific knowledge on the structure of physical activities? Which health-related goals can be sought with different physical activities in the field of sport? Which target groups can be reached with these kinds of sport? These questions are addressed in this article on the basis of current scientific knowledge-to promote the development of health-enhancing physical activities especially in sport federations, but also to create a communication platform between the sport and the health sector. The work of researchers in this field is focused mainly on health-enhancing physical activity, but they are also engaged in health-related scientific organizations and in sport federations.


Subject(s)
Evidence-Based Medicine , Health Promotion/methods , Motor Activity/physiology , Physical Fitness/physiology , Preventive Medicine/methods , Rehabilitation/methods , Humans
7.
B-ENT ; 7(1): 43-6, 2011.
Article in English | MEDLINE | ID: mdl-21563556

ABSTRACT

PROBLEMS/OBJECTIVES: Epstein-Barr virus (EBV) is commonly associated with nasopharyngeal carcinoma and Burkitt's lymphoma, but association with hypopharyngeal and laryngeal tumours is rare. To the best of our knowledge, this is the first case report of an EBV-associated diffuse large B-cell lymphoma (DLBCL) of the hypopharynx. METHODOLOGY: A 63-year-old male patient suffering from chronic lymphocytic leukemia presented with swallowing disorders and a sore throat. Panendoscopy with laser surgical resection of tissue specimens was performed. RESULTS: Immunohistochemical and molecular genetic diagnostics, including EBV-encoded small RNA in situ hybridization, confirmed the diagnosis of an EBV-associated DLBCL of the hypopharynx. Ten weeks after the diagnosis, the patient died of disease related to multiple complications. CONCLUSIONS: We hypothesize that the EBV infection was triggered by long-term immunosuppressive therapy that led secondarily to the development of a DLBCL. Otorhinolaryngologists should keep in mind that lymphomas might develop in the entire pharynx.


Subject(s)
Epstein-Barr Virus Infections/complications , Hypopharyngeal Neoplasms/virology , Lymphoma, Large B-Cell, Diffuse/virology , Epstein-Barr Virus Infections/epidemiology , Fatal Outcome , Humans , Hypopharyngeal Neoplasms/diagnostic imaging , Hypopharyngeal Neoplasms/epidemiology , Immunocompromised Host , Immunohistochemistry , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology , Lymphoma, Large B-Cell, Diffuse/diagnostic imaging , Lymphoma, Large B-Cell, Diffuse/epidemiology , Male , Middle Aged , Pyriform Sinus/virology , Tomography, X-Ray Computed
8.
Aktuelle Urol ; 40(2): 113-5, 2009 Mar.
Article in German | MEDLINE | ID: mdl-19177323

ABSTRACT

INTRODUCTION: First description of a prostate adenocarcinoma coinciding with the rare MALT lymphoma of the prostate. CASE REPORT: 68-year-old patient with a pT2c, pN0, M0, Gleason 3 + 3 prostate carcinoma (retropubic radical prostatectomy with pelvic lymphadenectomy) and systemic indolent MALT lymphoma of the prostate (bone marrow biopsy). Therapy and course are described and further explained by referring to case reports found in the literature. In this context, possible pathogenetic mechanisms, the prognosis for this special disease and possible therapeutic approaches are discussed. CONCLUSION: MALT lymphomas of the prostate are rare, and so far a coincidence with a prostate carcinoma is unprecedented. The prostate carcinoma is treated according to stage, while the MALT lymphoma is managed according to individual treatment strategies. The histopathological classification is more important for the prognosis. Treatment with antibiotics to eradicate possible copathogenic Helicobacter pylori is discussed as an innovative therapeutic approach. The pathogenesis of the MALT lymphoma of the prostate cannot yet be clarified definitively according to a literature review.


Subject(s)
Adenocarcinoma/surgery , Lymphoma, B-Cell, Marginal Zone/surgery , Neoplasms, Multiple Primary/surgery , Prostatic Neoplasms/surgery , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Marrow Neoplasms/pathology , Bone Marrow Neoplasms/secondary , Chemotherapy, Adjuvant , Combined Modality Therapy , Humans , Lymphoma, B-Cell, Marginal Zone/drug therapy , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Neoplasm Staging , Neoplasms, Multiple Primary/drug therapy , Neoplasms, Multiple Primary/pathology , Prostate/pathology , Prostatectomy , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology
10.
Hamostaseologie ; 27(4): 273-7, 2007 Sep.
Article in German | MEDLINE | ID: mdl-17938766

ABSTRACT

Malignant effusions are a frequent problem for cancer patients. Due to the high resistance of tumor cells within these effusions, no effective treatment has been defined yet. Most patients exhibit additional phenomena related to hyper-coagulability such as elevated levels for d-dimers and prothrombin fragments f1.2; half of them suffer from manifest thrombosis or complications. We followed the hypothesis that the activated coagulation system contributes to the resistance of tumor cells and analyzed the effusions from cancer patients. The majority of isolated tumor cells aberrantly expressed PAR-1 thrombin receptors. In vitro pre-incubation of PAR-1 expressing human leukemia cells with thrombin resulted in a dose-dependent resistance to idarubicin. Within the effusions, we did not only find high concentrations of VEGF and tissue factor, but also all coagulation factors of the tissue factor pathway. Very high levels of prothrombin fragments f1.2 indicate constant thrombin generation. Upon the basis of these findings, we developed a multistep model elucidating the pathophysiological generation of malignant effusions, which might serve as a basis for further examinations.


Subject(s)
Blood Coagulation/physiology , Pleural Effusion, Malignant/blood , Humans , Neoplasms/blood , Neoplasms/physiopathology , Receptor, PAR-1/physiology
11.
Appl Opt ; 46(14): 2683-7, 2007 May 10.
Article in English | MEDLINE | ID: mdl-17446918

ABSTRACT

Photorefractive spatial solitons are attractive elements because they can be used as controllable optical interconnectors for all-optical devices. To our knowledge, until now their properties were investigated in terms of energy transportation. We suggest considering photorefractive spatial solitons as optically induced information channels. The experimental technique to measure the information throughput of photorefractive spatial solitons in accordance with Shannon's definition was developed and demonstrated by us. We experimentally demonstrated that in the wavelength range of 1520-1630 nm it can be estimated as large as approximately 90 Tbits/s. We also experimentally demonstrate a measurement of the group-velocity dispersion and show the limitation of the pulse transfer rate of the induced waveguides to approximately 6.2 THz.

12.
Leukemia ; 21(2): 215-21, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17170730

ABSTRACT

Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain reference values for Ig/TCR rearrangement patterns, 19 European laboratories investigated 188 T-cell malignancies belonging to five World Health Organization-defined entities. The TCR/Ig spectrum of each sample was analyzed in duplicate in two different laboratories using the standardized BIOMED-2 PCR multiplex tubes accompanied by international pathology panel review. TCR clonality was detected in 99% (143/145) of all definite cases of T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma (unspecified) and angioimmunoblastic T-cell lymphoma (AILT), whereas nine of 43 anaplastic large cell lymphomas did not show clonal TCR rearrangements. Combined use of TCRB and TCRG genes revealed two or more clonal signals in 95% of all TCR clonal cases. Ig clonality was mostly restricted to AILT. Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms. The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.


Subject(s)
Genes, Immunoglobulin , Leukemia, T-Cell/genetics , Lymphoma, T-Cell/genetics , Polymerase Chain Reaction/methods , Receptors, Antigen, T-Cell/genetics , Gene Amplification , Gene Rearrangement , Genotype , Humans , Immunohistochemistry , Leukemia, Prolymphocytic/genetics , Leukemia, Prolymphocytic/immunology , Leukemia, Prolymphocytic/pathology , Leukemia, T-Cell/immunology , Leukemia, T-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/immunology , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, T-Cell/immunology , Lymphoma, T-Cell/pathology , T-Lymphocytes/immunology
14.
Histopathology ; 47(5): 493-500, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16241997

ABSTRACT

AIMS: Irradiation-induced sialadenitis is a significant cause of morbidity in head and neck cancer patients receiving radiotherapy. Neither the exact aetiopathology of chronic irradiation-induced sialadenitis nor the mechanisms leading to atrophy of the glandular cells associated with an increase in extracellular matrix are understood. The aim of our study was to determine the phenotype of the inflammatory infiltrate and to study its distribution in the affected submandibular glands. METHODS AND RESULTS: Paraffin-embedded submandibular glands from a homogeneous group of 19 patients with advanced oropharyngeal cancer who received conventional radiotherapy to the primary site and upper neck were analysed. In all patients the radiation dose and field were approximately equal. The submandibular glands were obtained during neck dissection. To characterize the lymphoid infiltrate, all tissue sections were immunostained for T cells (CD3, CD4, CD8), cytotoxic T cells (granzyme B), B cells (CD20), and macrophages (Ki-M1p). A histopathological classification into four grades was established based on the degree of glandular atrophy, fibrosis and lymphocytic infiltration. Phenotypic analysis of submandibular gland sections revealed that the great majority of lymphocytic infiltrates were cytotoxic T cells associated with acinar cell destruction. CONCLUSIONS: The significantly elevated frequencies of cytotoxic cells in the submandibular glands of patients with irradiation-induced sialadenitis suggest that cell-mediated immune mechanisms may play a part in the pathogenesis of this disease.


Subject(s)
Lymphocyte Subsets/radiation effects , Radiation Injuries/pathology , Sialadenitis/pathology , Submandibular Gland/pathology , Adult , Aged , Chronic Disease , Female , Humans , Lymphocyte Subsets/pathology , Male , Middle Aged , Oropharyngeal Neoplasms/radiotherapy
15.
Br J Cancer ; 93(8): 939-45, 2005 Oct 17.
Article in English | MEDLINE | ID: mdl-16189522

ABSTRACT

Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with a monoclonal antibody against MCM6. The percentage of MCM6 expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (P<0.0001). Surprisingly, the ratio of MCM6-positive cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, P<0.0001). Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL.


Subject(s)
Cell Cycle Proteins/biosynthesis , Lymphoma, Mantle-Cell/genetics , Lymphoma, Mantle-Cell/pathology , Biopsy , Cell Cycle Proteins/genetics , Cell Proliferation , Female , Gene Expression Profiling , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Lymph Nodes/pathology , Male , Middle Aged , Minichromosome Maintenance Complex Component 6 , Multivariate Analysis , Predictive Value of Tests , Prognosis , Survival Analysis
16.
Oral Microbiol Immunol ; 20(3): 163-6, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15836517

ABSTRACT

The purpose of this study was to investigate the expression of human beta-defensins (hBD-1, -2) in dental pulps by reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. The mRNA transcripts of human beta-defensin-1 and human beta-defensin-2 could be detected by performing RT-PCR. With immunohistochemical staining of pulp tissue using antisera to hBD-1 and -2 it was possible to demonstrate cytoplasmic expression in odontoblasts. The results demonstrate that not only oral keratinocytes at the epithelial surface but also odontoblasts express human beta-defensins. Thus odontoblasts take part in the innate immune system and human beta-defensins may play an important role in the innate host defense of human dental pulp.


Subject(s)
Dental Pulp/chemistry , beta-Defensins/analysis , Adolescent , Adult , Dental Pulp/immunology , Humans , Immunohistochemistry , Reverse Transcriptase Polymerase Chain Reaction
17.
Leuk Lymphoma ; 46(2): 285-8, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15621815

ABSTRACT

We describe successful treatment of a 38-year-old patient with composite lymphoma stage IV(A), who presented with multifocal enlarged lymph nodes. The lymph node histology showed classic morphologic features of Hodgkin's disease, mixed cellularity subtype and follicular B-cell lymphoma. Immunophenotypic analysis showed immunoreactivity for CD20, CD10 and Ki-67 in the malignant small cell population. The areas of Hodgkin's disease demonstrated positive immunoreactivity for CD30 and CD20 in the Hodgkin's cells. Both cell populations were bcl2-oncoprotein positive. Eight courses of dose-escalated BEACOPP were administered. Restaging after chemotherapy showed radiological partial remission, but biopsy confirmed persisting follicular B-cell lymphoma without bone marrow infiltration and no evidence of Hodgkin's disease. He was treated with monoclonal CD 20-antibody (Rituximab) 10 mg/kg weekly for eight consecutive weeks due to marked positivity of CD 20-antigen in follicular lymphoma cells. This treatment was well tolerated and final staging showed complete remission of the composite lymphoma. This patient continues to be in remission 28 months after the end of the treatment. In conclusion, in the very rare case of composite lymphoma a combination of chemotherapy and subsequent immunotherapy might be considered as a promising therapeutic option.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma/drug therapy , Adult , Antibodies, Monoclonal, Murine-Derived , Antigens, CD20 , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Humans , Ki-67 Antigen , Leukemia, Lymphoid/drug therapy , Leukemia, Lymphoid/pathology , Lymphoma/pathology , Male , Neprilysin , Remission Induction/methods , Rituximab
18.
Zentralbl Neurochir ; 65(4): 191-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15551184

ABSTRACT

UNLABELLED: A 47-year-old man was admitted to our hospital with a nine-week history of visual disturbance, headache, disorientation and facial nerve palsy. Serial cranial magnetic resonance imaging (MRI) revealed progressive bilateral occipital edema with hemorrhage and meningeal involvement. There were no hints of hereditary or acquired immunodeficiency. Laboratory examination for bacterial and viral causes was negative. Open brain biopsy revealed primary central nervous system lymphoma of the extraordinary rare so-called "peripheral" T-cell type. The further course was fatal; the patient died 10 weeks after the onset of symptoms from tumor progression before planned chemotherapy could be started. CONCLUSION: If primary central nervous system lymphoma (PCNSL) is suspected, brain biopsy -- either open biopsy or stereotactic biopsy -- should be performed straight away to enable a rapid start of chemotherapy and/or radiotherapy. Peripheral T-cell lymphoma was highly aggressive in this case leading to the patient's death within several weeks.


Subject(s)
Central Nervous System Neoplasms/pathology , Lymphoma, T-Cell/pathology , Biopsy , Brain Edema/complications , Brain Edema/diagnostic imaging , Brain Edema/etiology , Central Nervous System Neoplasms/complications , Central Nervous System Neoplasms/diagnostic imaging , Cerebral Hemorrhage/complications , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/etiology , Fatal Outcome , Humans , Immunohistochemistry , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/diagnostic imaging , Magnetic Resonance Imaging , Male , Middle Aged , Radiography
19.
Leukemia ; 18(7): 1200-6, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15116121

ABSTRACT

Mantle cell lymphoma (MCL) is a malignant lymphoma associated with a relatively aggressive clinical course and a median overall survival time of 3-4 years. Treatment usually consists of combination chemotherapy, often including topoisomerase (topo) inhibitors such as doxorubicin, etoposide and mitoxantrone. Topo IIalpha is an enzyme that is needed whenever uncoiling of DNA is necessary during the cell cycle. The enzyme is a marker of cell proliferation. We analyzed the expression of topo IIalpha in relation to Ki-67 and the clinical outcome in patients with MCL. Biopsy specimens from 95 untreated patients enrolled in two multicenter trials (1975-1985) were investigated immunohistochemically with monoclonal antibodies against topo IIalpha (Ki-S4) and Ki-67 (Ki-S5). Patients with low (0-10%) topo IIalpha expression had a median overall survival time of 49.0 months, compared to 17.0 months for patients with high (more than 10%) topo IIalpha expression. The Kaplan-Meier analysis showed a significant difference in the overall survival time related to the percentage of topo IIalpha (P<0.001) and Ki-67 (P<0.001) positive tumor cells. Multivariate Cox regression analysis revealed the expression of topo IIalpha as the most important prognostic factor (P<0.001) in MCL superior to the international prognostic index (IPI), the Ki-67 index and other clinical characteristics.


Subject(s)
DNA Topoisomerases, Type II/analysis , Lymphoma, Mantle-Cell/enzymology , Antigens, Neoplasm , Antineoplastic Agents/therapeutic use , Biomarkers/analysis , Cell Division , DNA-Binding Proteins , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/mortality , Male , Middle Aged , Prognosis , Regression Analysis , Survival Analysis , Treatment Outcome
20.
Pathologe ; 25(1): 63-72, 2004 Feb.
Article in German | MEDLINE | ID: mdl-14767614

ABSTRACT

This tutorial focuses on malignant lymphomas and inflammatory conditions as potential precursors of primary malignant lymphomas in salivary glands. Salivary glands display a mucosa-associated lymphoid tissue and are often associated with intra- and periglandular lymph nodes. Inflammation of the glands may variably produce duct ectasia, lymphoepithelial lesions, atrophy, and fibrosis. Primary lymphomas of the salivary glands may develop on the basis of autoimmune sialadenitis and comprise most frequently marginal zone lymphomas, less often monocytoid lymphomas or other lymphoma entities. In a large proportion of cases, lymphoma infiltrates are attributable to extraglandular lymphomas either as a leukemic infiltrate with diffuse enlargement or as a localized manifestation of primary nodal non-Hodgkin lymphomas. Diagnosis is based on conventional histology and immunohistology.


Subject(s)
Lymphoma/pathology , Salivary Gland Neoplasms/pathology , Humans , Lymphoma/epidemiology , Lymphoma, B-Cell, Marginal Zone/pathology , Mucous Membrane/pathology , Salivary Gland Neoplasms/epidemiology , Sialadenitis/etiology , Sialadenitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...